Shenzhen Sunwin Intelligent vs Axon Enterprise: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shenzhen Sunwin Intelligent (300044.CS)

Axon Enterprise Inc. (AXON)

Q3 202612 Jul – 21 Aug 2026

▲3▼1

Axon's record Q2 and raised outlook drive growth story

Record Q2 revenue and raised full-year outlook Axon reported Q2 revenue of $904 million, up 35% year over year, and raised its 2026 revenue growth guidance to 32-34% from 30-32%. This shows strong demand for its products and boosts investor confidence in future growth.
This is the core new event that directly lifts Axon's growth prospects and stock price.
Strong bookings and recurring revenue Future contracted bookings jumped 41% to $15.1 billion, and annual recurring revenue rose 39% to $1.6 billion with net revenue retention at 126%. This means customers are committing to more Axon products and services, providing predictable future income.
It highlights the underlying demand strength that supports the raised outlook and long-term growth.
Q2 earnings miss and margin pressure Despite revenue growth, adjusted earnings per share of $1.88 missed the consensus estimate of $1.89, and net income fell to $29 million from $36 million a year earlier. This shows costs are rising and profitability is under pressure, which can weigh on the stock.
It provides the main counterweight to the positive revenue news and explains why the stock dropped after earnings.
New Taser product (Apollo) on track Axon is close to finalizing its Apollo cartridge, a new Taser designed to outperform a nine-millimeter bullet, with a target release by next winter. This innovation could open new markets and drive future sales.
It is a new product development that supports the long-term growth narrative beyond current results.

August 202612 Jul – 21 Aug 2026

▲3▼1

Axon's record Q2 and raised outlook drive growth story

Record Q2 revenue and raised full-year outlook Axon reported Q2 revenue of $904 million, up 35% year over year, and raised its 2026 revenue growth guidance to 32-34% from 30-32%. This shows strong demand for its products and boosts investor confidence in future growth.
This is the core new event that directly lifts Axon's growth prospects and stock price.
Strong bookings and recurring revenue Future contracted bookings jumped 41% to $15.1 billion, and annual recurring revenue rose 39% to $1.6 billion with net revenue retention at 126%. This means customers are committing to more Axon products and services, providing predictable future income.
It highlights the underlying demand strength that supports the raised outlook and long-term growth.
Q2 earnings miss and margin pressure Despite revenue growth, adjusted earnings per share of $1.88 missed the consensus estimate of $1.89, and net income fell to $29 million from $36 million a year earlier. This shows costs are rising and profitability is under pressure, which can weigh on the stock.
It provides the main counterweight to the positive revenue news and explains why the stock dropped after earnings.
New Taser product (Apollo) on track Axon is close to finalizing its Apollo cartridge, a new Taser designed to outperform a nine-millimeter bullet, with a target release by next winter. This innovation could open new markets and drive future sales.
It is a new product development that supports the long-term growth narrative beyond current results.

Latest12 Jul – 21 Aug 2026

▲3▼1

Axon's record Q2 and raised outlook drive growth story

Record Q2 revenue and raised full-year outlook Axon reported Q2 revenue of $904 million, up 35% year over year, and raised its 2026 revenue growth guidance to 32-34% from 30-32%. This shows strong demand for its products and boosts investor confidence in future growth.
This is the core new event that directly lifts Axon's growth prospects and stock price.
Strong bookings and recurring revenue Future contracted bookings jumped 41% to $15.1 billion, and annual recurring revenue rose 39% to $1.6 billion with net revenue retention at 126%. This means customers are committing to more Axon products and services, providing predictable future income.
It highlights the underlying demand strength that supports the raised outlook and long-term growth.
Q2 earnings miss and margin pressure Despite revenue growth, adjusted earnings per share of $1.88 missed the consensus estimate of $1.89, and net income fell to $29 million from $36 million a year earlier. This shows costs are rising and profitability is under pressure, which can weigh on the stock.
It provides the main counterweight to the positive revenue news and explains why the stock dropped after earnings.
New Taser product (Apollo) on track Axon is close to finalizing its Apollo cartridge, a new Taser designed to outperform a nine-millimeter bullet, with a target release by next winter. This innovation could open new markets and drive future sales.
It is a new product development that supports the long-term growth narrative beyond current results.

Q2 202619 Jun – 2 Jul 2026

▲3

Axon's AI and counter-drone boom, plus federal contract hopes, drive the stock

AI and software revenue surge Axon's AI product revenue jumped over 700% and software revenue rose 35%, pushing Q1 revenue up 34% to $807 million. Management raised full-year growth guidance to 30-32%. This shows the company's core business is growing much faster than expected, which supports a higher stock price.
This is the fundamental growth driver behind the stock's move and a new guidance raise.
Counter-drone platform Dedrone takes off Axon's Dedrone counter-drone business grew about 300% year-over-year and has already brought in more bookings than its purchase price. The 2026 World Cup is a near-term opportunity. This fast-growing new product line adds a fresh revenue stream and boosts investor excitement.
Dedrone's rapid growth is a new, concrete driver of future revenue and stock momentum.
Trump stake and ICE contract signal federal demand President Trump bought $1M-$5M of Axon stock in February, and ICE later sought a $220M Taser contract matching Axon's specs. While the contract isn't awarded and no wrongdoing is proven, the news suggests more federal business ahead, lifting the stock.
This is a major new catalyst that directly boosted the stock by 10% and points to potential federal contracts.
Political controversy and valuation risk Axon faces scrutiny over alleged involvement in a Scottsdale city council race, which could hurt its reputation with public agencies. Also, the stock trades at a very high price-to-earnings ratio near 100 and is still 30% below its peak, so any bad news could trigger sharp drops.
This is the main counterweight: reputational and valuation risks that could push the stock down despite strong growth.

June 202619 Jun – 2 Jul 2026

▲3

Axon's AI and counter-drone boom, plus federal contract hopes, drive the stock

AI and software revenue surge Axon's AI product revenue jumped over 700% and software revenue rose 35%, pushing Q1 revenue up 34% to $807 million. Management raised full-year growth guidance to 30-32%. This shows the company's core business is growing much faster than expected, which supports a higher stock price.
This is the fundamental growth driver behind the stock's move and a new guidance raise.
Counter-drone platform Dedrone takes off Axon's Dedrone counter-drone business grew about 300% year-over-year and has already brought in more bookings than its purchase price. The 2026 World Cup is a near-term opportunity. This fast-growing new product line adds a fresh revenue stream and boosts investor excitement.
Dedrone's rapid growth is a new, concrete driver of future revenue and stock momentum.
Trump stake and ICE contract signal federal demand President Trump bought $1M-$5M of Axon stock in February, and ICE later sought a $220M Taser contract matching Axon's specs. While the contract isn't awarded and no wrongdoing is proven, the news suggests more federal business ahead, lifting the stock.
This is a major new catalyst that directly boosted the stock by 10% and points to potential federal contracts.
Political controversy and valuation risk Axon faces scrutiny over alleged involvement in a Scottsdale city council race, which could hurt its reputation with public agencies. Also, the stock trades at a very high price-to-earnings ratio near 100 and is still 30% below its peak, so any bad news could trigger sharp drops.
This is the main counterweight: reputational and valuation risks that could push the stock down despite strong growth.

19 Jun – 2 Jul 2026

▲3

Axon's AI and counter-drone boom, plus federal contract hopes, drive the stock

AI and software revenue surge Axon's AI product revenue jumped over 700% and software revenue rose 35%, pushing Q1 revenue up 34% to $807 million. Management raised full-year growth guidance to 30-32%. This shows the company's core business is growing much faster than expected, which supports a higher stock price.
This is the fundamental growth driver behind the stock's move and a new guidance raise.
Counter-drone platform Dedrone takes off Axon's Dedrone counter-drone business grew about 300% year-over-year and has already brought in more bookings than its purchase price. The 2026 World Cup is a near-term opportunity. This fast-growing new product line adds a fresh revenue stream and boosts investor excitement.
Dedrone's rapid growth is a new, concrete driver of future revenue and stock momentum.
Trump stake and ICE contract signal federal demand President Trump bought $1M-$5M of Axon stock in February, and ICE later sought a $220M Taser contract matching Axon's specs. While the contract isn't awarded and no wrongdoing is proven, the news suggests more federal business ahead, lifting the stock.
This is a major new catalyst that directly boosted the stock by 10% and points to potential federal contracts.
Political controversy and valuation risk Axon faces scrutiny over alleged involvement in a Scottsdale city council race, which could hurt its reputation with public agencies. Also, the stock trades at a very high price-to-earnings ratio near 100 and is still 30% below its peak, so any bad news could trigger sharp drops.
This is the main counterweight: reputational and valuation risks that could push the stock down despite strong growth.